Michael H Kiefer

US Patent:

6436639, Aug 20, 2002

Filed:

Dec 7, 1999

Appl. No.:

09/367750

Inventors:

Michael C. Kiefer - Clayton CA
Natalya K. Ossina - Albany CA

Assignee:

Tanox, Inc. - Houston TX

International Classification:

C12Q 168

US Classification:

435 6, 435243, 435325, 435410, 536 241

Abstract:

Polynucleotides which regulate the expression of a gene involved in apoptosis is described. Also provided are methods for identifying agents that modulate expression of a gene involved in apoptosis.

US Patent:

6441135, Aug 27, 2002

Filed:

Feb 11, 2000

Appl. No.:

09/381488

Inventors:

Michael C. Kiefer - Clayton CA
Paul A. Fitzpatrick - Albany CA
Helen L. Gibson - Oakland CA
Philip J. Barr - Oakland CA

Assignee:

Tanox, Inc. - Houston TX

International Classification:

C07K 100

US Classification:

530350, 530300, 435 71, 435 691, 536 231

Abstract:

The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention neither provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the âBBP Binding Domainsâ and the respective nucleotides, designated âbbpbd-1â and âbbpbd-2â which arc involved in the interaction between Bak and BBP.

US Patent:

6500635, Dec 31, 2002

Filed:

Nov 28, 1994

Appl. No.:

08/345864

Inventors:

Michael C. Kiefer - Clayton CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C12P 2106

US Classification:

435 691, 4353201, 4352523, 435325, 536 231, 530350, 530303, 5303871, 5303881, 514 2, 514 3

Abstract:

A purified insulin-like growth factor binding protein (IGFBP) selected from the group consisting of insulin-like growth factor binding protein having an amino acid sequence that, preferably, is at least 70% homologous to the amino acid sequence of FIG. and fragments thereof that are capable of binding to an antibody specific for the protein or to an insulin-like growth factor is described. This new IGFBP is designated herein as IGFBP-5. Recombinant DNA molecules encoding the binding proteins and subsequences thereof are also described along, with recombinant microorganisms and cell lines containing the DNA molecules and methods for producing the binding proteins using recombinant hosts containing the relevant DNA molecules. Antibodies to the protein, useful in various diagnostic applications, are also described.

US Patent:

6586395, Jul 1, 2003

Filed:

Jun 6, 1995

Appl. No.:

08/470865

Inventors:

Michael C. Kiefer - Clayton CA
Philip J. Barr - Berkeley CA

Assignee:

Tanox, Inc. - Houston TX

International Classification:

A61K 3816

US Classification:

514 12, 514 2, 530350

Abstract:

The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to novel homologs of bcl-2 designated CDN-1, CDN-2, and CDN-3, and fragments, variants, homologs and derivatives thereof, which are capable of modulating apoptosis.

US Patent:

6864061, Mar 8, 2005

Filed:

Sep 13, 2001

Appl. No.:

09/952571

Inventors:

Allan S. Lau - Pok Fu Lan, HK
Michael C. Kiefer - Clayton CA, US

Assignee:

GeneTrol Biotherapeutics, Inc. - Oakland CA

International Classification:

G01N033/53
G01N033/567
C12N005/10
C12N015/12
C12N015/63

US Classification:

435 71, 435 72, 435 721, 435325, 435 691, 435471, 4352523, 4353201

Abstract:

A method and cell line for screening test compounds for anti-inflammatory activity are disclosed. The cell line is a human cell line capable of producing a selected cytokine associated with an inflammatory response in humans, and transfected with (i) a vector containing DNA encoding a cytokine regulatory factor under the control of a first promoter, and (ii) a vector containing DNA encoding a detectable-marker protein, under the control of a second promoter which is responsive to cytokine induction. In the screening method, the cells are cultured under conditions of cytokine regulatory factor overexpression and cytokine induction. Addition of test compound that results in a diminution of the detectable-marker protein is evidence of anti-inflammatory activity.

US Patent:

6903195, Jun 7, 2005

Filed:

Aug 7, 2000

Appl. No.:

09/633200

Inventors:

Michael C. Kiefer - Clayton CA, US
Philip J. Barr - Berkeley CA, US

Assignee:

Tanox, Inc. - Houston TX

International Classification:

C07K016/00
G01N033/53
G01N033/567

US Classification:

5303871, 5303881, 53038815, 5303888, 5303891, 5303897, 435 71, 435 721, 435 724

Abstract:

The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.

US Patent:

6906029, Jun 14, 2005

Filed:

Nov 19, 2002

Appl. No.:

10/300498

Inventors:

Michael C. Kiefer - Clayton CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C01K014/00

US Classification:

514 3, 512 2, 530399, 530303, 530350

Abstract:

A purified insulin-like growth factor binding protein (IGFBP) selected from the group consisting of insulin-like growth factor binding protein having an amino acid sequence that, preferably, is at least 70% homologous to the amino acid sequence of FIG. and fragments thereof that are capable of binding to an antibody specific for the protein or to an insulin-like growth factor is described. This new IGFBP is designated herein as IGFBP-6. Recombinant DNA molecules encoding the binding proteins and subsequences thereof are also described along with recombinant microorganisms and cell lines containing the DNA molecules and methods for producing the binding proteins using recombinant hosts containing the relevant DNA molecules. Antibodies to the protein, useful in various diagnostic applications, are also described.

US Patent:

7108989, Sep 19, 2006

Filed:

Mar 18, 2002

Appl. No.:

10/101482

Inventors:

Michael C. Kiefer - Clayton CA, US
Philip J. Barr - Berkeley CA, US

Assignee:

Tanox, Inc. - Houston TX

International Classification:

G01N 33/53

US Classification:

435 72, 435 71, 435 691, 536 231

Abstract:

The present invention provides a method of screening for a biological modifier that modulates apoptosis-induced cell death by contacting a cell expressing CDN-1 or fragments or variants thereof with a potential biological modifier and measuring the level of apoptosis-induced cell death induced thereby.

Address:

750 Tabor St APT 23, Lakewood, CO 80401

Phone:

(720)8374400

VIN:

4S3BMDK61B2250392

Make:

SUBARU

Model:

LEGACY

Year:

2011